Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Short-term Investments (2016 - 2025)

Assembly Biosciences has reported Short-term Investments over the past 11 years, most recently at $189.7 million for Q4 2025.

  • Quarterly results put Short-term Investments at $189.7 million for Q4 2025, up 157.21% from a year ago — trailing twelve months through Dec 2025 was $189.7 million (up 157.21% YoY), and the annual figure for FY2025 was $189.7 million, up 157.21%.
  • Short-term Investments for Q4 2025 was $189.7 million at Assembly Biosciences, down from $210.0 million in the prior quarter.
  • Over the last five years, Short-term Investments for ASMB hit a ceiling of $210.0 million in Q3 2025 and a floor of $19.6 million in Q3 2023.
  • Median Short-term Investments over the past 5 years was $73.7 million (2022), compared with a mean of $88.3 million.
  • Biggest five-year swings in Short-term Investments: tumbled 63.77% in 2023 and later skyrocketed 240.09% in 2024.
  • Assembly Biosciences' Short-term Investments stood at $101.0 million in 2021, then crashed by 61.2% to $39.2 million in 2022, then surged by 181.71% to $110.4 million in 2023, then tumbled by 33.21% to $73.7 million in 2024, then surged by 157.21% to $189.7 million in 2025.
  • The last three reported values for Short-term Investments were $189.7 million (Q4 2025), $210.0 million (Q3 2025), and $51.0 million (Q2 2025) per Business Quant data.